Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

Thierry Conroy,Najib Lamfichekh,Pierre-Luc Etienne,Emmanuel Rio,Eric Francois,Nathalie Mesgouez-Nebout,Véronique Vendrely,Xavier Artignan,Olivier Bouché,Dany Gargot,Valérie Boige,N. Bonichon-Lamichhane,Christophe Louvet,Clotilde Morand,Christelle De La Fouchardiere,Beata Juzyna,Eric Rullier,Frédéric Marchal,Florence Castan,Christophe Borg

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

2020

4007Background: PRODIGE 23 investigated the role of neoadjuvant mFOLFIRINOX before preoperative (preop) chemoradiation (CRT), with TME-surgery and adjuvant chemotherapy (CT) in resectable locally a...

Keywords:

locally advanced
Colorectal cancer
Radiology
Neoadjuvant therapy
Medicine
Physical therapy
preoperative chemoradiotherapy
in patient
adjuvant chemotherapy
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations